Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P, Nasdaq futures slip as markets await Iran sanctions, Nvidia results
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'
May 22, 2025 2:50 PM EDT(Updated - May 22, 2025 2:52 PM EDT)
Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "In response to Novo lowering the cash pay price of Wegovy to $199 for the first month... More
Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS
May 22, 2025 11:34 AM EDTCiti analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "With the end of 503B bulk compounding of commercially available semaglutide today, NovoCare announced a promotion offering cash pay access to Wegovy for $199... More
